journal
Journals Annals of Oncology : Official ...

Annals of Oncology : Official Journal of the European Society for Medical Oncology

https://read.qxmd.com/read/38583574/timing-of-radiotherapy-rt-after-radical-prostatectomy-rp-long-term-outcomes-in-the-radicals-rt-trial-nct00541047
#1
JOURNAL ARTICLE
C C Parker, P M Petersen, A D Cook, N W Clarke, C Catton, W R Cross, H Kynaston, W R Parulekar, R A Persad, F Saad, L Bower, G C Durkan, J Logue, C Maniatis, D Noor, H Payne, J Anderson, A K Bahl, F Bashir, D M Bottomley, K Brasso, L Capaldi, P W Cooke, C Chung, J Donohue, B Eddy, C M Heath, A Henderson, A Henry, R Jaganathan, H Jakobsen, N D James, J Joseph, K Lees, J Lester, H Lindberg, A Makar, S L Morris, N Oommen, P Ostler, L Owen, P Patel, A Pope, R Popert, R Raman, V Ramani, A Røder, I Sayers, M Simms, V Srinivasan, S Sundaram, K L Tarver, A Tran, P Wells, J Wilson, A M Zarkar, M K M Parmar, M R Sydes
BACKGROUND: The optimal timing of radiotherapy (RT) after radical prostatectomy for prostate cancer has been uncertain. RADICALS-RT compared efficacy and safety of adjuvant RT versus an observation policy with salvage RT for PSA failure. METHODS: RADICALS-RT was a randomised controlled trial enrolling patients with ≥1 risk factor (pT3/4, Gleason 7-10, positive margins, pre-op PSA≥10ng/ml) for recurrence after radical prostatectomy. Patients were randomised 1:1 to adjuvant RT ("Adjuvant-RT") or an observation policy with salvage RT for PSA failure ("Salvage-RT") defined as PSA≥0...
April 5, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38579969/identifying-genetic-loci-associated-with-an-increased-risk-for-early-onset-colorectal-cancer
#2
EDITORIAL
David Kelsen, Irit Ben-Aharon, Noa Gordon
No abstract text is available yet for this article.
April 3, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38555024/oncogenic-extrachromosomal-dna-identification-using-whole-genome-sequencing-from-formalin-fixed-glioblastomas
#3
LETTER
Imran Noorani, Jens Luebeck, Andrew Rowan, Eva Gronroos, Vittorio Barbe, Mark Fabian, James Nicoll, Delphine Boche, Vineet Bafna, Paul S Mischel, Charles Swanton
No abstract text is available yet for this article.
March 28, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38548063/reporting-and-analysis-of-immunotherapy-trials-adverse-events-what-is-going-wrong-how-to-do-better
#4
LETTER
I Pourmir, R Nebbache, S Champiat, O Lambotte
No abstract text is available yet for this article.
March 26, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38537779/tumor-mutational-burden-for-the-prediction-of-pd-l-1-blockade-efficacy-in-cancer-challenges-and-opportunities
#5
REVIEW
X Wang, G Lamberti, A Di Federico, J Alessi, R Ferrara, M L Sholl, M M Awad, Vokes N, B Ricciuti
Tumor mutational burden (TMB) is a biomarker that measures the number of somatic mutations in a tumor's genome. TMB has emerged as a predictor of response to immune checkpoint inhibitors (ICIs) in various cancer types, and several studies have shown that patients with high TMB have better outcomes when treated with PD-(L)1-based therapies. Recently, the FDA has approved TMB as a companion diagnostic for the use of pembrolizumab in solid tumors. However, despite its potential, the use of TMB as a biomarker for immunotherapy efficacy is limited by several factors...
March 25, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38490358/esmo-clinical-practice-guideline-interim-update-on-first-line-therapy-in-advanced-urothelial-carcinoma
#6
T Powles, J Bellmunt, E Comperat, M De Santis, R Huddart, Y Loriot, A Necchi, B P Valderrama, A Ravaud, S F Shariat, B Szabados, M S van der Heijden, S Gillessen
No abstract text is available yet for this article.
March 13, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38484973/residual-disease-post-neoadjuvant-chemo-immunotherapy-in-early-triple-negative-breast-cancer-does-it-help-tailor-adjuvant-treatment
#7
EDITORIAL
Elisa Agostinetto, Laurence Buisseret, Roberto Salgado, Marleen Kok, Michail Ignatiadis
No abstract text is available yet for this article.
March 12, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38484972/new-adcs-bring-new-questions-in-egfr-nsclc-and-beyond
#8
EDITORIAL
S Scott, B Levy
No abstract text is available yet for this article.
March 12, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38431043/adding-immunotherapy-to-first-line-treatment-of-advanced-and-metastatic-endometrial-cancer
#9
REVIEW
G Bogani, B J Monk, M A Powell, S N Westin, B Slomovitz, K N Moore, R N Eskander, F Raspagliesi, M-P Barretina-Ginesta, N Colombo, M R Mirza
BACKGROUND: Immunotherapy has transformed the endometrial cancer treatment landscape , particularly for those exhibiting mismatch repair deficiency (MMRd/MSI-H). A growing body of evidence supports the integration of immunotherapy with chemotherapy as a first-line treatment strategy. Recently, findings from ongoing trials such as RUBY (NCT03981796), NRG-GY018 (NCT03914612), AtTEnd (NCT03603184), and DUO-E (NCT04269200) have been disclosed. MATERIALS AND METHODS: This paper constitutes a review and meta-analysis of phase III trials investigating the role of immunotherapy in the first-line setting for advanced or recurrent endometrial cancer...
February 29, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38423389/early-prediction-of-endocrine-responsiveness-in-er-her2-negative-metastatic-breast-cancer-mbc-pilot-study-with-18f-fluoroestradiol-18f-fes-ct-pet
#10
JOURNAL ARTICLE
A Gennari, E Brain, A De Censi, O Nanni, R Wuerstlein, A Frassoldati, J Cortes, V Rossi, M Palleschi, J L Alberini, F Matteucci, A Piccardo, G Sacchetti, H Ilhan, F D'Avanzo, B Ruffilli, S Nardin, M Monti, M Puntoni, V Fontana, L Boni, N Harbeck
BACKGROUND: 18F-FES PET/CT is considered an accurate diagnostic tool to determine whole-body endocrine responsiveness. In the ET-FES trial, we evaluated 18F-FES PET/CT as a predictive tool in ER+/HER2- metastatic breast cancer (MBC). METHODS: Eligible patients underwent a 18F-FES PET/CT at baseline. Patients with SUV≥2 received single agent ET until PD; patients with SUV<2 were randomized to single agent ET (Arm A) or chemotherapy (CT) (Arm B). Primary objective was to compare the activity of first line ET versus CT in patients with 18F-FES SUV <2...
February 27, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38408508/genome-wide-association-study-and-mendelian-randomization-analyses-provide-insights-into-the-causes-of-early-onset-colorectal-cancer
#11
JOURNAL ARTICLE
R S Laskar, C Qu, J R Huyghe, T Harrison, R B Hayes, Y Cao, P T Campbell, R Steinfelder, F R Talukdar, H Brenner, S Ogino, S Brendt, D T Bishop, D D Buchanan, A T Chan, M Cotterchio, S B Gruber, A Gsur, B van Guelpen, M A Jenkins, T O Keku, B M Lynch, L Le Marchand, R M Martin, K McCarthy, V Moreno, R Pearlman, M Song, K K Tsilidis, P Vodička, M O Woods, K Wu, L Hsu, M J Gunter, U Peters, N Murphy
BACKGROUND: The incidence of early-onset colorectal cancer (EOCRC; diagnosed <50 years of age) is rising globally; however, the causes underlying this trend are largely unknown. Colorectal cancer (CRC) has strong genetic and environmental determinants, yet common genetic variants and causal modifiable risk factors underlying EOCRC are unknown. We conducted the first EOCRC-specific genome-wide association study (GWAS) and Mendelian randomization analyses to explore germline genetic and causal modifiable risk factors associated with EOCRC...
February 24, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38382875/four-year-overall-survival-update-from-the-phase-iii-himalaya-study-of-tremelimumab-plus-durvalumab-in-unresectable-hepatocellular-carcinoma
#12
JOURNAL ARTICLE
B Sangro, S L Chan, R K Kelley, G Lau, M Kudo, W Sukeepaisarnjaroen, M Yarchoan, E N De Toni, J Furuse, Y K Kang, P R Galle, L Rimassa, A Heurgué, V C Tam, T Van Dao, S C Thungappa, V Breder, Y Ostapenko, M Reig, M Makowsky, M J Paskow, C Gupta, J F Kurland, A Negro, G K Abou-Alfa
BACKGROUND: In the phase III HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS. Results reported herein are from a 4-year updated OS analysis of HIMALAYA. PATIENTS AND METHODS: Participants with uHCC and no previous systemic treatment were randomized to STRIDE (n = 393), durvalumab (n = 389), or sorafenib (n = 389)...
February 19, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38369015/event-free-survival-by-residual-cancer-burden-with-pembrolizumab-in-early-stage-tnbc-exploratory-analysis-from-keynote-522
#13
JOURNAL ARTICLE
L Pusztai, C Denkert, J O'Shaughnessy, J Cortes, R Dent, H McArthur, S Kümmel, J Bergh, Y H Park, R Hui, N Harbeck, M Takahashi, M Untch, P A Fasching, F Cardoso, Y Zhu, W Pan, K Tryfonidis, P Schmid
BACKGROUND: KEYNOTE-522 demonstrated statistically significant improvements in pathological complete response (pCR) with neoadjuvant pembrolizumab plus chemotherapy and event-free survival (EFS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with high-risk, early-stage triple-negative breast cancer (TNBC). Prior studies have shown the prognostic value of the residual cancer burden (RCB) index to quantify the extent of residual disease after neoadjuvant chemotherapy...
February 17, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38369014/peritoneal-effusion-an-uncommon-adverse-effects-of-selective-ret-inhibitors
#14
LETTER
C Belli, G Curigliano
No abstract text is available yet for this article.
February 16, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38369013/translational-insights-and-overall-survival-in-the-u31402-a-u102-study-of-patritumab-deruxtecan-her3-dxd-in-egfr-mutated-nsclc
#15
JOURNAL ARTICLE
H A Yu, C Baik, D-W Kim, M L Johnson, H Hayashi, M Nishio, J C-H Yang, W-C Su, K A Gold, M Koczywas, E F Smit, C E Steuer, E Felip, H Murakami, S-W Kim, X Su, S Sato, P-D Fan, M Fujimura, Y Tanaka, P Patel, D Sternberg, D Sellami, P A Jänne
BACKGROUND: HER3 is broadly expressed in NSCLC and is the target of patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. U31402-A-U102 is an ongoing phase 1 study of HER3-DXd in patients with advanced NSCLC. Patients with EGFR-mutated NSCLC that progressed after EGFR TKI and platinum-based chemotherapy (PBC) who received HER3-DXd 5.6 mg/kg intravenously once every 3 weeks had a confirmed objective response rate (cORR) of 39%...
February 16, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38364991/the-co-expression-of-antigen-targets-as-a-rationale-for-adcs-combination-in-urothelial-cancer
#16
LETTER
F Bertucci, A DE Nonneville, P Finetti, A Cohendet, A Guille, E Mamessier
No abstract text is available yet for this article.
February 14, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38417742/treatment-patterns-and-outcomes-in-metastatic-castration-resistant-prostate-cancer-patients-with-and-without-somatic-or-germline-alterations-in-homologous-recombination-repair-genes
#17
JOURNAL ARTICLE
D Olmos, D Lorente, D Alameda, C Cattrini, N Romero-Laorden, R Lozano, P P Lopez-Casas, A Jambrina, C Capone, A M Vanden Broecke, M Trevisan, S Van Sanden, A Jürgens, B Herrera-Imbroda, E Castro
BACKGROUND: Although germline BRCA mutations have been associated with adverse outcomes in prostate cancer (PC), understanding of the association between somatic/germline alterations in homologous recombination repair (HRR) genes and treatment outcomes in metastatic castration-resistant PC (mCRPC) is limited. The aim of this study was to investigate the prevalence and outcomes associated with somatic/germline HRR alterations, particularly BRCA1/2, in patients initiating first-line (1L) mCRPC treatment with androgen receptor signalling inhibitors (ARSi) or taxanes...
February 10, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38342185/centralisation-of-care-improves-overall-survival-for-sarcoma-patients
#18
EDITORIAL
A Napolitano, K Thway, P Huang, R L Jones
No abstract text is available yet for this article.
February 9, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38342184/does-b-stand-for-benefit-decoding-the-b-cell-neighborhood-in-head-and-neck-cancer-for-predicting-therapeutic-response-to-pd1-inhibitors
#19
EDITORIAL
B B Y Ma, D W T Lim
No abstract text is available yet for this article.
February 9, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38311210/sensitivity-of-a-blood-ctdna-based-multimodal-test-for-the-detection-of-advanced-colorectal-neoplasms
#20
LETTER
H Brenner, T Niedermaier, M Hoffmeister
No abstract text is available yet for this article.
February 2, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
journal
journal
30452
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.